Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response. by 源��룄�쁺 et al.
ORiginal Article
Gut and Liver, Vol. 10, No. 3, May 2016, pp. 429-436
Predicting Liver-Related Events Using Transient Elastography in Chronic 
Hepatitis C Patients with Sustained Virological Response
Hye Won Lee*,†, Young Eun Chon*,†, Seung Up Kim*,†,‡, Beom Kyung Kim*,†,‡, Jun Yong Park*,†,‡, Do Young Kim*,†,‡, 
Sang Hoon Ahn*,†,‡,§, Kyu Sik Jung*,†, Young Nyun ParkΙΙ, and Kwang-Hyub Han*,†,‡,§
*Department of Internal Medicine, †Institute of Gastroenterology, ‡Liver Cirrhosis Clinical Research Center, §Brain Korea 21 Project for Medical 
Science, and ΙΙDepartment of Pathology, Yonsei University College of Medicine, Seoul, Korea 
Correspondence to: Seung Up Kim
Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea 
Tel: +82-2-2228-1982, Fax: +82-2-393-6884, E-mail: ksukorea@yuhs.ac
Received on January 11, 2015. Revised on April 21, 2015. Accepted on April 23, 2015.  Published online September 9, 2015
pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl15021
Hye Won Lee and Young Eun Chon contributed equally to this work as first authors.
Background/Aims: Few studies have investigated prognos-
tic factors for the development of liver-related events (LREs) 
in patients with chronic hepatitis C (CHC) who achieve sus-
tained virological response (SVR). Methods: We analyzed 
190 patients with CHC who achieved SVR after treatment 
with pegylated interferon (peg-IFN) plus ribavirin. LREs were 
defined as any complications related to cirrhosis, hepatocel-
lular carcinoma (HCC), or liver-related mortality. Results: The 
mean age was 54.1 years, and 84 of the patients (44.2%) 
were male. The mean liver stiffness (LS) value at SVR was 
7.1±5.4 kPa. During the follow-up period (median, 43.0 
months), LREs occurred in 10 patients (5.3%; HCC in eight 
patients, ascites in one patient, and liver-related mortality in 
one patient). By multivariate Cox regression analysis, age, 
α-fetoprotein level, and LS value were independent predic-
tors for LRE development (all p<0.05). Patients with LS 
values ≥7.0 kPa had a greater risk (hazard ratio, 9.472; 95% 
confidence interval, 1.018 to 88.126; p=0.048) for LRE de-
velopment compared to those with LS values <7.0 kPa. Con-
clusions: The LS value at SVR is useful for predicting LRE de-
velopment in CHC patients who achieve SVR after treatment 
with peg-IFN plus ribavirin. Thus, LRE surveillance strategies 
might be optimized according to the LS values at SVR, even 
with complete viral eradication. (Gut Liver 2016;10:429-
436)
Key Words: Hepatitis C, chronic; Carcinoma, hepatocellular; 
Liver stiffness; Sustained virological response; Transient 
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INTRODUCTION
The achievement of a sustained virological response (SVR) 
to treatment with pegylated interferon (peg-IFN) plus ribavirin 
is a surrogate for the cure of infection in patients with chronic 
hepatitis C (CHC) and regarded as a very important favorable 
predictor to prevent disease progression.1-4 In addition, it is 
well known that SVR can significantly reduce the risk of the 
development of liver-related events (LREs), such as hepatocel-
lular carcinoma (HCC), hepatic decompensation, or liver-related 
death.5,6 However, in spite of successful hepatitis C virus (HCV) 
eradication by antiviral therapy, the risk of LRE development 
cannot always be alleviated, mainly due to residual advanced 
fibrosis or cirrhosis.7 Thus, the assessment of residual fibrotic 
burden in patients with CHC who achieve SVR is of paramount 
importance, not only for prognostication but also for defining 
an effective surveillance program for the early detection of LRE 
development, because the degree of liver fibrosis is significantly 
associated with the risk of LRE development.8
SVR can lead to regression of liver fibrosis and cirrhosis.9,10 
Thus, it can be a routine strategy to perform liver biopsy (LB) to 
assess the degree of the residual liver fibrosis immediately after 
achieving SVR. However, this diagnostic approach has not been 
widely used due to several reasons. First, although LB has been 
the gold standard to assess the degree of liver fibrosis, LB is an 
invasive procedure with the rare but potential risk of life-threat-
ening complications.11 Second, LB has an inherent sampling 
error and interpretational variability even among experienced 
pathologists.12 Therefore, the development of a noninvasive tool 
that can accurately assess the degree of fibrotic burden at SVR 
can have important clinical implications.
Recently, the measurement of liver stiffness (LS) using tran-
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sient elastography (TE) has proven a reliable and noninvasive 
tool in assessing the amount of fibrosis in patients with chronic 
viral hepatitis.13 Based on the accumulated literature, TE has 
been endorsed by the European Association for the Study of the 
Liver (EASL) as a noninvasive tool to stage liver fibrosis before 
commencing antiviral treatment in patients with CHC.14-16 In 
contrast, in a more recent cross-sectional study,17 TE showed 
suboptimal performance in diagnosing cirrhosis at SVR, as 
a consequence of liver remodeling and fibrosis reabsorption 
through antiviral therapy. However, it is unknown whether LS 
measurement using TE can predict long-term outcomes after the 
achievement of SVR from a longitudinal perspective.
Thus, the aim of our study was to investigate whether LS 
values obtained using TE at SVR, which reflect the remaining 
fibrotic burden, can predict LRE development in patients with 
CHC who achieved SVR after peg-IFN plus ribavirin therapy.
MATERIALS AND METHODS
1. Patients 
Patients with CHC who had been treated with peg-IFN plus 
ribavirin therapy and underwent LS measurement using TE 
at SVR at Severance Hospital, Yonsei University College of 
Medicine, Seoul, Korea, between May 2005 and August 2014, 
were considered eligible. Patients who did not achieve SVR 
due to following reasons were excluded: (1) nonresponders, (2) 
relapsers, (3) follow-up loss, or (4) incomplete treatment due to 
poor compliance or adverse events. Although all the patients 
achieved SVR, some patients were excluded based on the fol-
lowing exclusion criteria: (1) co-infection with hepatitis B virus 
or human immunodeficiency virus, (2) other serious concur-
rent illness (e.g., alcoholism, uncontrolled diabetes, or cancer), 
(3) hepatic decompensation at enrollment or a prior history of 
decompensation, (4) HCC at enrollment or a previous history of 
HCC, (5) unavailable LS measurement or invalid LS values, and 
(6) follow-up loss or follow-up period less than 6 months after 
SVR (Fig. 1).
Written informed consent was obtained from all study par-
ticipants. This study was approved by the independent Institu-
tional Review Board of Severance Hospital (IRB number: 2013-
1030-002) and conformed to the ethical guidelines of the 1975 
Helsinki Declaration.
2. Treatment protocol and follow-up
Patients were treated with either 180 μg peg-IFN-α2a once 
per week or 1.5 μg peg-IFN-α2b per week. Ribavirin (15 mg/
kg body weight per day) was given for patients with genotype 
1, and a flat dose of 800 mg was given for patients with geno-
type 2 or 3. During peg-IFN plus ribavirin therapy, all patients 
were seen at baseline and then 2 to 4 weeks. At every visit, a 
complete blood cell count, routine blood chemistry tests, com-
pliance, and adverse events were checked. HCV RNA levels were 
checked at baseline, at the end of treatment, and at 6 months 
after the end of treatment. Thereafter, patients visited every 6 
to 12 months to monitor the HCV RNA level. Serum HCV RNA 
levels were quantified using commercial polymerase chain reac-
tion assays (Amplicor HCV or Roche Diagnostics, Seoul, Korea). 
SVR was defined as the presence of undetectable HCV RNA lev-
els at the end of treatment and at follow-up 6 months after the 
end of treatment. Serum aspartate aminotransferase and alanine 
aminotransferase (ALT) levels were measured using standard 
laboratory procedures with the upper limit of normal set at 40 
IU/mL for both. During the follow-up period, all patients under-
went periodic surveillance with ultrasonography and laboratory 
work-ups, including checking the level of α-fetoprotein (AFP) 
every 3 or 6 months to screen for HCC and other portal hyper-
tension-related complications. The end of follow-up period was 
March 2015.
3. LS measurement using TE
In all patients, LS measurement using TE was performed 
when SVR was confirmed. TE examinations were done by a 
single experienced technician (>20,000 examinations) who 
was blinded to patient information. Results were expressed in 
256 CHC patients treated with
peg-IFN+ribavirin
234 CHC patients with
sustained virological response
190 Patients were finally analyzed
1) Non-responders
2) Relapsers
3) Follow-up loss
4) Incomplete treatment due to poor compliance
or adverse events
1) Co-infection with hepatitis B virus or HIV
2) Other serious concurrent illness
3) Hepatic decompensation at enrollment or a prior
history of decompensation
4) HCC at enrollment or a previous history of HCC
5) Unavailable LS measurement or invalid LS values
6) Follow-up loss or follow-up period <6 months after SVR
Fig. 1. Recruitment algorithm. A 
total of 256 patients with chronic 
hepatitis C (CHC) who were treated 
with pegylated interferon (peg-
IFN) and ribavirin were enrolled. 
Of these, 66 patients were excluded 
based on our exclusion criteria. A 
final total of 190 patients were se-
lected for statistical analysis. 
HIV, human immunodeficiency vi-
rus; HCC, hepatocellular carcinoma; 
LS, liver stiffness; SVR, sustained 
virological response.
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kilopascal (kPa), and the median of successful measurements 
was selected as the representative LS value. The interquartile 
range (IQR) was defined as an index of intrinsic variability of 
LS values corresponding to the interval of LS results contain-
ing 50% of the valid measurements between the 25th and 75th 
percentiles. In this study, only measurements with at least 10 
valid shots, a success rate of at least 60%, and an IQR to median 
value ratio (IQR/M) of <0.3 were considered reliable and used 
for statistical analysis.18
4. Definition of liver cirrhosis and LREs
If histological information was not available, clinically diag-
nosed liver cirrhosis was defined as follows: (1) platelet count 
<100,000/μL and ultrasonographic findings suggestive of cir-
rhosis, including a blunted, nodular liver edge accompanied by 
splenomegaly (>12 cm); or (2) esophageal or gastric varices.19
The primary endpoint was to evaluate whether LS values can 
predict LRE development in patients with CHC who achieved 
SVR. LREs were defined as a cirrhotic complication (ascites, 
variceal bleeding, spontaneous bacterial peritonitis, hepatic en-
cephalopathy, and hepatorenal syndrome), HCC, and/or liver-
related mortality. If a patient experienced different types of 
LREs at different time points, we selected only the earliest LRE 
for statistical analysis. 
5. Statistical analyses
Data are expressed as the mean±standard deviation, median 
(range), or number (%) as appropriate. Differences between con-
tinuous and categorical variables were examined for statistical 
significance with Student t-test (or Mann-Whitney test, if ap-
propriate) and chi-square test (or Fisher exact test, if appropri-
ate). Patients were censored at the time of the first presentation 
of a LRE or at the last follow-up. LRE rates were calculated 
using the Kaplan-Meier method and were compared with the 
log-rank test. The Cox proportional hazards model was used for 
multivariate analyses. Time-dependent areas under the receiver 
operating characteristic curves (AUROCs) were evaluated to esti-
mate the predictive performance of models for LRE development 
risk. All statistical analyses were assessed using SPSS version 
20.0 (IBM Corp., Armonk, NY, USA). A p-value <0.05 was con-
sidered statistically significant.
RESULTS
1. Baseline characteristics
A total of 256 patients with CHC who were treated with peg-
IFN plus ribavirin were recruited. All patients were treatment-
naive. However, 66 patients were excluded based on our exclu-
sion criteria. Finally, 190 patients were included in the analyses 
(Fig. 1). The baseline characteristics of our study population are 
summarized in Table 1. The mean age (84 men and 106 women) 
was 54.1 years. Liver cirrhosis was identified in 85 patients 
(44.7%), and all patients had well-preserved liver function of 
Child-Pugh class A. HCV genotype 1 was present in 109 pa-
tients (57.4%). The mean LS value at SVR was 7.1±5.4 kPa. 
2. LRE development
During the follow-up period (median, 43.0 months; range, 
Table 1. Baseline Characteristics at Sustained Virological Response 
(n=190)
Variable Value
Demographic variable
    Age, yr 54.1±11.4
    Male sex 84 (44.2)
    Body mass index, kg/m2 23.6±3.1
    Diabetes mellitus 31 (16.3)
    Hypertension 35 (18.4)
Treatment variable
    HCV genotype
        1/2 or 3 109 (57.4)/81 (42.6)
    IFN regimen
        Peg-IFNα-2a/2b 126 (66.3)/64 (33.7)
Laboratory variable
    Alanine aminotransferase, IU/L 20.3±15.4
    Serum albumin, g/dL 4.3±0.4
    Total bilirubin, mg/dL 0.8±0.3
    Prothrombin time, INR 0.9±0.1
    α-Fetoprotein, ng/mL 3.51±3.8
    Total cholesterol, mg/dL 164.2±42.3
Clinical liver cirrhosis 85 (44.7)
Child-Pugh score 5/6 189 (99.5)/1 (0.5)
Liver stiffness measurement
    Liver stiffness values, kPa 7.1±5.4
    Interquartile range, kPa 1.5±0.8
    Interquartile range/median, % 25.2±17.6
    Success rate, % 95±10
Data are presented as mean±SD or number (%).
HCV, hepatitis C virus; peg-IFN, pegylated interferon; INR, interna-
tional normalized ratio; kPa, kilopascal.
Table 2. Liver-Related Events (n=10)
Variable Value
Follow-up period after SVR, mo 43.0 (6.0–120.0)
Time to LRE development after SVR, mo 22.8 (8.4–71.1)
Type of LREs
    Decompensation 1 (10.0)
    Hepatocellular carcinoma 8 (80.0)
    Liver-related death 1 (10.0)
Data are presented as median (range) or number (%).
SVR, sustained virological response; LRE, liver-related events.
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6.0 to 120.0 months), 10 patients (5.3%) experienced LRE devel-
opment (HCC in eight patients, ascitic decompensation in one 
patient, and liver-related mortality in one patient) (Table 2). The 
cumulative incidences of LRE development at 1, 2, and 3 years 
were 0.5%, 1.1%, and 2.1%, respectively (an annual incidence 
rate of 3.90/1,000 person-years [PYs]) (Fig. 2). The median 
time to LRE occurrence after SVR was 22.8 months (range, 8.4 
to 71.1 months) (Table 2). The first HCC was diagnosed at 8.4 
months after achieving SVR; this patient exhibited an LS value 
of 14.1 kPa at SVR and had single HCC with 1.3 cm in diam-
eter. The median time from SVR to HCC diagnosis was 19.4 
months (range, 8.4 to 52.7 months); these patients had median 
LS values of 7.8 kPa (range, 6.1 to 26.6 kPa) at SVR. Ascitic 
decompensation developed in one patient, which was diagnosed 
at 30.7 months after SVR (LS value, 25.0 kPa at SVR). Six of the 
eight patients with HCC had clinical liver cirrhosis.
3. Comparison between patients with and without develop-
ment of LRE after SVR
The clinical characteristics of patients with and without LRE 
development are shown in Table 3. LS values were significantly 
higher in patients with LRE development than in those without 
(mean, 16.6 kPa vs 6.8 kPa, p<0.001). Age, male gender, ALT 
level, AFP level, and the proportion of liver cirrhosis were also 
significantly higher in patients with LRE development than 
those without (all p<0.05). The risk of LRE development was 
statistically similar according to HCV genotype (1 vs 2 or 3) and 
the type of antiviral agents (peg-IFN-α2a or α2b).
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Fig. 2. Cumulative incidence rates of liver-related event (LRE) devel-
opment. The cumulative incidence rates of LRE development at 1, 2, 
and 3 years were 0.5%, 1.1%, and 2.1%, respectively.
AFP, α-fetoprotein.
Table 3. Comparison between Patients with and without Liver-Related Event Development
Variable
Patients with LRE
(n=10, 5.3%)
Patients without LRE
(n=180, 94.7%)
p-value
Demographic variable
    Age, yr 66.8±6.3 53.4±11.2 0.024
    Male sex 8 (80.0) 76 (42.2) <0.001
    Body mass index, kg/m2 23.6±1.9 23.6±3.2 NS
    Diabetes mellitus 2 (20.0) 29 (16.1) NS
    Hypertension 1 (10.0) 34 (18.9) NS
Treatment variable
    HCV genotype 1 7 (70.0) 102 (56.7) NS
    Peg-IFNα-2a 6 (60.0) 120 (66.7) NS
Laboratory variable
    Alanine aminotransferase, IU/L 39.1±58.0 19.3±7.8 <0.001
    Serum albumin, g/dL 4.1±0.4 4.4±0.4 NS
    Total bilirubin, mg/dL 0.9±0.3 0.7±0.3 NS
    Prothrombin time, INR 1.0±0.1 0.9±0 1 NS
    α-Fetoprotein, ng/mL 9.7±8.8 3.0±2.5 <0.001
    Total cholesterol, mg/dL 145.3±34.1 160.0±42.3 NS
Clinical liver cirrhosis 8 (80.0) 77 (42.8) 0.017
Child-Pugh score 5 10 (100.0) 179 (99.4) 0.005
Liver stiffness measurement
    Liver stiffness values, kPa 16.6±6.4 6.8±5.2 <0.001
Data are presented as mean±SD or number (%).
LRE, liver-related event; NS, not significant; HCV, hepatitis C virus; peg-IFN, pegylated interferon; INR, international normalized ratio; kPa, kilo-
pascal.
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4. Risk factors for LRE development
In univariate Cox regression analyses, age, AFP level, and LS 
values were selected as significant predictors for LRE develop-
ment (Table 4). The time-dependent AUROC value for age, AFP 
level, and LS values were 0.877 (95% confidence interval [CI], 
0.781 to 0.973), 0.762 (95% CI, 0.556 to 0.969), and 0.920 (95% 
CI, 0.843 to 0.996), respectively. The cutoff values for age (≥65 
years vs <65 years; sensitivity, 80.0%; specificity, 85.2%), AFP 
level (≥6.0 ng/mL vs <6.0 ng/mL; sensitivity, 80.0%; specificity, 
85.1%), and LS values (≥7.0 kPa vs <7.0 kPa; sensitivity, 80.0%; 
specificity, 88.5%) were calculated to maximize their diagnostic 
accuracy.
In subsequent multivariate analysis, age ≥65 years, AFP level 
≥6.0 ng/mL, and LS value ≥7.0 kPa independently predicted LRE 
development with a hazard ratio (HR) of 8.230 (95% CI, 1.323 
to 51.187; p=0.024), 11.363 (95% CI, 1.348 to 95.793; p=0.025), 
and 9.472 (95% CI, 1.018 to 88.126; p=0.048), respectively 
(Table 4). The cumulative incidence rates of LRE development 
increased significantly in patients with older age, higher AFP 
level, and higher LS values at SVR (log-rank test, all p<0.05) (Fig. 
3). The 3-year cumulative incidence rate of LRE development 
was significantly higher in older patients (24.8% in patients 
aged ≥65 years vs 1.4% in those aged <65 years; HR, 18.500; 
95% CI, 3.750 to 91.257; p<0.001), those with higher AFP level 
(28.6% in patients with AFP ≥6.0 ng/mL vs 2.4% in those with 
AFP level <6.0 ng/mL; HR, 26.522; 95% CI, 4.757 to 144.539; 
p<0.001), and those with higher LS values (26.2% in patients 
with LS values ≥7.0 kPa vs 0.9% in those with LS values <7.0 
kPa; HR, 24.562; 95% CI, 3.031 to 199.039; p=0.003).
DISCUSSION 
The achievement of SVR is considered the single most im-
portant predictor for prognostication of disease progression in 
patients with CHC.2-4 Nowadays, although increasing numbers 
of patients achieve SVR with the introduction of direct-acting 
antivirals (DAAs) such as telaprevir or boceprevir,20 there still 
exists a sustained risk of LRE development, such as HCC, he-
patic decompensation, or liver-related death.5,7,21 This is mainly 
due to residual advanced fibrosis even after the regression of 
cirrhosis by successful treatment represented as SVR. However, 
the clinical implication of residual fibrotic burden in patients 
who achieved SVR has not been sufficiently investigated. Only 
a few studies have emphasized that patients with regressed cir-
rhosis had lower incidence of LREs,10 because the assessment 
of regression of cirrhosis at SVR by LB is not clinically feasible 
due to its potential invasiveness. Therefore, we evaluated the 
Table 4. Independent Factors Associated with Liver-Related Event Development after Sustained Virological Response
Variable
Univariate Multivariate
p-value Hazard ratio (95% CI) p-value
Demographic variables
    Age ≥65 yr (vs <65 yr) <0.001 8.230 (1.323–51.187) 0.024
    Male sex NS - -
    Body mass index, kg/m2 NS - -
    Diabetes mellitus NS - -
    Hypertension NS - -
Treatment variable
    Genotype 1 (vs 2 or 3) NS - -
    peg-INFα-2a (vs 2b) NS - -
Laboratory variable
    Alanine aminotransferase NS -  -
    Serum albumin, g/dL NS - -
    Total bilirubin, mg/dL NS - -
    Prothrombin time, INR NS - -
    α-Fetoprotein ≥6.0 ng/mL (vs <6.0 ng/mL) <0.001 11.363 (1.348–95.793) 0.025
    Total cholesterol, mg/dL NS - -
Clinical liver cirrhosis NS - -
Child-Pugh score NS - -
Liver stiffness measurement
    Liver stiffness values ≥7.0 kPa (vs <7.0 kPa) 0.003 9.472 (1.018–88.126) 0.048
CI, confidence interval; NS, not significant; peg-IFN, pegylated interferon; INR, international normalized ratio; kPa, kilopascal.
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residual fibrotic burden in patients at SVR using TE, which has 
been well validated for assessing the degree of liver fibrosis in 
patients with chronic viral hepatitis. Our results show that the 
LS value at SVR can independently predict future LRE develop-
ment.
In our study, a total of ten LREs developed (eight HCC, one 
ascetic decompensation and liver-related mortality). The HCC 
incidence rate was 0.7 per 100 PYs, which is consistent with 
results from previous studies reporting the reduced but persis-
tent risk of HCC incidence as approximately 1 per 100 PYs after 
SVR achievement.5,22 Similar to a previous study by Aleman et 
al.,5 which showed the possibility of delayed HCC development 
after SVR, one patient in our cohort experienced HCC develop-
ment at 71 months after SVR. All these observations indicate 
that the risk of HCC development, albeit minimal, can last for a 
prolonged time after SVR achievement and highlight the impor-
tance of long-term periodic surveillance for HCC in spite of SVR 
achievement. In addition, the incidence rate of hepatic decom-
pensation was also low, similar to other previous studies,2,5 but 
developed in one patient after SVR in our cohort.
Interestingly, three out of eight patients who developed HCC 
showed relatively low LS values at SVR (7.6, 7.9, and 6.1 kPa, 
respectively). This is even more intriguing because two patients 
who showed noncirrhotic ranges of LS values (7.6 and 7.9 kPa, 
respectively) had clinical cirrhosis. Although the exact reason 
for this phenomenon is unclear, it can be explained in part by 
liver remodeling after SVR achievement. Because SVR results in 
an improvement of most histological features of cirrhosis, such 
as fibrosis amount, activity and stages, LS values, which have 
strong correlations with these histological parameters, might 
decrease accordingly below the cirrhotic range.9,23 In addition, 
liver cell regeneration, which generally happens most actively 
at SVR,17 might soften the texture of the liver parenchyma and 
thus cause lower LS values. However, because the nodular con-
figuration can exist unchanged even after SVR, it was possible 
to make a diagnosis of clinical liver cirrhosis. This hypothesis 
can be supported by a recent study by D’Ambrosio et al.,17 
which showed that among patients who were predicted to have 
regressed cirrhosis based on the presence of LS values <12.0 
kPa, 21% still had histological features of liver cirrhosis at the 
concurrent LB at SVR.
Because LS values do not represent the structure of fibrosis 
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Fig. 3. Cumulative incidence rates of liver-related event (LRE) devel-
opment based on stratified age and liver stiffness values. The cumu-
lative incidence rates of LRE development increased significantly in 
older patients (A), those with higher α-fetoprotein (AFP) levels (B), 
and those with higher liver stiffness (LS) values at sustained virologi-
cal response (C) (log-rank test, all p<0.05).
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but the amount, TE may not be suitable tool for defining liver 
cirrhosis, especially in patients with CHC at SVR. However, it 
was proved through our study that the prognostic role of the LS 
value for predicting LRE development after SVR should not be 
underestimated. First, the LS value was selected as one of in-
dependent predictors for LRE development even after adjusting 
the influence of clinical liver cirrhosis. Second, among patients 
with clinical liver cirrhosis, the mean LS value of patients with 
LRE development (n=8) was significantly higher than those of 
patients without LRE development (n=77) (13.7 kPa vs 6.4 kPa, 
p<0.001).
To date, only few of studies have proposed various prognos-
tic factors including age, AFP, or ALT level at SVR in patients 
with CHC.22,24 Oze et al.22 and Asahina et al.24 concluded that 
AFP level at SVR is an independent predictor for HCC occur-
rence. They explained this phenomenon by the fact that high 
AFP levels at SVR can indicate the proliferative activity of liver 
cells, which may result in hepatocarcinogenesis. Similarly, AFP 
level was also selected as one of independent predictors of HCC 
development after SVR and the calculated cutoff AFP level was 
strikingly same as the cutoff from a previous study by Asahina 
et al. (6 ng/mL). However, the study by Oze et al.22 and Asahina 
et al.,24 did not adjust for the residual fibrotic burden, the single 
most important factor for HCC development, at SVR; therefore, 
further investigation with a large sample size and TE data will 
be required to validate our current results.
Our study has several strengths. To our knowledge, this is 
the first study that involved the LS value obtained using TE for 
predicting LRE development in patients with CHC who achieved 
SVR. In our study, patients with LS value ≥7.0 kPa , AFP ≥6 ng/
mL and age ≥65 years at SVR had 9-, 11- and 8-fold higher risk 
for LRE development than their counterparts. Second, in this era 
of effective antiviral treatment including DAAs, complete viral 
eradication has become possible in more than 90% of patients 
with CHC.25,26 Thus, the clinical implication of predicting anti-
viral efficacy, reflected by the achievement of SVR, has been 
attenuated, but it has become important to predict long-term 
prognosis after SVR. Measurement of the LS value at SVR can 
resolve this issue to a certain extent. Third, LS values at SVR 
when necroinflammation subsides and ALT level is normalized 
accordingly can be more reliable in assessing the fibrotic burden 
without confounding effects, because LS values at the initiation 
of antiviral treatment could overestimate fibrosis burden due to 
high ALT levels. 
We are also aware of several issues which still remain unre-
solved. First, as LB data at SVR were not available, we could not 
evaluate the relationships among the residual fibrotic burden, 
LS values, and prognosis. The relatively small sample size, small 
number of LREs, and the short-term follow-up period are limita-
tions as well. Future large-scale studies with sufficient histologi-
cal data and longer follow-up periods can resolve these issues. 
In conclusion, the LS value at SVR is useful for predicting 
LRE development in patients with CHC who achieved SVR 
through peg-IFN plus ribavirin therapy. Because patients with 
LS values ≥7.0 kPa have higher risk for LRE development, LRE 
surveillance strategies might be optimized according to LS val-
ues at SVR, even with complete viral eradication.
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